Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Levetiracetam reverses synaptic deficits produced by overexpression of SV2A.

PloS one - 1 Jan 2011

Nowack Amy, Malarkey Erik B, Yao Jia, Bleckert Adam, Hill Jessica, Bajjalieh Sandra M

Abstract excerpt

Levetiracetam is an FDA-approved drug used to treat epilepsy and other disorders of the nervous system. Although it is known that levetiracetam binds the synaptic vesicle protein SV2A, how drug binding affects synaptic functioning remains unknown. Here we report that levetiracetam reverses the effects of excess SV2A in autaptic hippocampal neurons. Expression of an SV2A-EGFP fusion protein produced a ∼1.5-fold...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Green Fluorescent Proteins
Share to Membrane Glycoproteins
Share to Neurotransmitter Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Presynaptic Terminals

Share to Protein Transport

Share to Recombinant Fusion Proteins

Share to Synapses

Share to Synaptotagmins

Source

Open in PubMed Open full text

Identifiers

PMID: 22220214
DOI: 10.1371/journal.pone.0029560
PMCID: PMC3248421

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Levetiracetam reverses synaptic deficits produced by overexpression of SV2A.PMID 22220214Read ↗

SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release.Semantic proximity Read ↗

SV2 regulates neurotransmitter release via multiple mechanisms.Semantic proximity Read ↗

Development and Validation of a New Mouse Model to Investigate the Role of SV2A in Epilepsy.Semantic proximity Read ↗

Homozygous Mutation in Synaptic Vesicle Glycoprotein 2A Gene Results in Intractable Epilepsy, Involuntary Movements, Microcephaly, and Developmental and Growth Retardation.Semantic proximity Read ↗

Behavioural phenotyping reveals anxiety-like features of SV2A deficient mice.Semantic proximity Read ↗

PRRT2 Is a Key Component of the Ca2+-Dependent Neurotransmitter Release MachinerySemantic proximity Read ↗

Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson’s diseaseSemantic proximity Read ↗

A de novo missense mutation in synaptotagmin-1 associated with neurodevelopmental disorder desynchronizes neurotransmitter releaseSemantic proximity Read ↗

Discovery of Heterocyclic Nonacetamide Synaptic Vesicle Protein 2A (SV2A) Ligands with Single‐Digit Nanomolar Potency: Opening Avenues towards the First SV2A Positron Emission Tomography (PET) LigandsSemantic proximity Read ↗

Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.Semantic proximity Read ↗

Disease-causing mutations in Synaptotagmin can act via dominant-negative, gain-of-function or haploinsufficient mechanismsSemantic proximity Read ↗

Synaptophysin is a β-Amyloid Target that Regulates Synaptic Plasticity and Seizure Susceptibility in an Alzhiemer’s ModelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.